BCL2 and hepatocellular carcinoma: Therefore, the well-known decrease of MCL-1 induced by sorafenib [11, 16], combined to BCL-xL/BCL-2 reduction by RNA silencing or ABT-263 treatment, could be enough to cause hepatoma cell death as previously reported [16, 26].